



CHEMGENEX  
PHARMACEUTICALS

# Corporate Overview

January 2010

[www.chemgenex.com](http://www.chemgenex.com)

ASX:CXS

# Safe Harbor Statement and Recognition of Trademarks

Certain statements made herein that use the words “estimate”, “project”, “intend”, “expect”, “believe,” and similar expressions are intended to identify forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties which could cause the actual results, performance or achievements of the company to be materially different from those which may be expressed or implied by such statements, including, among others, risks or uncertainties associated with the development of the company’s technology, the ability to successfully market products in the clinical pipeline, the ability to advance promising therapeutics through clinical trials, the ability to establish our fully integrated technologies, the ability to enter into additional collaborations and strategic alliances and expand current collaborations and obtain milestone payments, the ability of the company to meet its financial requirements, the ability of the company to protect its proprietary technology, potential limitations on the company’s technology, the market for the company’s products, government regulation in Australia and the United States, changes in tax and other laws, changes in competition and the loss of key personnel. These statements are based on our management’s current expectations and are subject to a number of uncertainties that could change the results described in the forward looking statements. Investors should be aware that there are no assurances that results will not differ from those projected.

OMAPRO™ is a trademark of ChemGenex Pharmaceuticals Limited



# Overview




- Oncology focused biopharmaceutical company
  - Expertise in hematologic malignancies
  - Small molecule drugs with novel mechanisms of action targeting unmet medical needs
- Lead asset Omapro™ (omacetaxine) proven effective in TKI Resistant Chronic Myeloid Leukemia (CML)
  - Under FDA and EMEA review with initial indication in T315I+ patients
  - Targeted approvals: U.S. in H1 2010, EU in Q4 2010
- Partnered omacetaxine in Europe, Middle East and Africa
- Preparing for U.S. market launch with experienced management team

# Corporate Strategy



- U.S. commercialization targeted for 2010
  - Targeted approval H1 2010, followed by launch
- Partnered with Hospira in Europe, the Middle East, parts of Africa
  - Upfront payment of A\$17.8 million
  - Potential for an additional A\$119.4 million based on development and sales milestones plus royalties (CML only)
  - Further milestones and royalties possible with future indications
  - Strong alignment of strategic intent
- ChemGenex retains ROW product rights including North America

# Omapro™ (omacetaxine mepesuccinate)






# The CML Market & Current Treatment Options

# Paradigm Shift in the Management of CML



- Chronic Myeloid Leukemia (CML)
  - Chronic malignancy of the bone marrow
  - 5,000 new cases per annum in the U.S.
  - Worldwide prevalence >200,000 patients and growing
- First Line Therapy: Imatinib approved in 2001
  - Targeted tyrosine kinase inhibitor (TKI)
  - Global sales of US\$3.7 billion in 2008 (60-70% in CML)
- Second Line Therapy: Two approved TKIs
  - Dasatinib approved in June 2006
  - Nilotinib approved in October 2007


# Reductions in Mortality Increase CML Prevalence



# The USA CML Market

## CML Treatment Distribution

(Patients treated – 29,555 )



Source: IntrinsiQ April 2009

## Pricing of Approved Drugs


Drug	Daily Dose	Annual Average Warehouse Price (US\$)
Imatinib	400mg	52,800
	600mg	82,118
	800mg	105,601
Dasatinib	100mg	87,936
	140mg	87,936
Nilotinib	400mg	49,304
	600mg	73,956

Source: Red Book Q2 2009

# TKI Failure is an Emerging Problem in CML

- Failure develops in current treatment options
  - After 5 years on therapy, 37% of imatinib treated patients did not achieve a successful outcome<sup>1</sup>
- The T315I+ mutation is the most frequent (15-20%)<sup>2</sup>
  - 44% of imatinib failures have mutations<sup>3</sup>
- Omapro has a unique mechanism of action that works differently than other TKIs
  - Specifically binds the ribosomal A-site cleft inhibiting protein translation<sup>4</sup>
  - Selectively reduces the levels of short-lived oncoproteins that are upregulated in leukemic cells<sup>5</sup>
  - Demonstrated, *in vitro*, to kill human CML stem cells and peripheral leukemic cells<sup>6</sup>

# Omapro Addresses Unmet Medical Needs in CML




Omapro™

for the treatment of CML

# A Potential New Treatment for CML Patients


- Omapro™ (omacetaxine mepesuccinate) for subcutaneous injection
- Convenient and safe BID administration
  - Induction – up to 14 days per month
  - Maintenance – up to 7 days per month
- Myelosuppression is the most common side effect and is normally manageable and reversible
- On track for 2010 approval and launch
  - NDA submitted September 2009, Priority Review
    - Orphan Drug designations in CML and MDS
  - MAA validated November 2009
    - Orphan Drug designation in CML



# Phase 2/3 Clinical Trials

	STUDY 202 CML T315I+ Patients	STUDY 203 Multiple TKI Failure CML
Design	Open label, Single arm	Open label, Single arm
Patients	Up to 100 patients	Up to 100 patients
Sites	35 in US, EU, Asia Pacific	35 in US, EU, Asia Pacific
Inclusion criteria	Patients who have failed imatinib and have T315I+ Bcr-Abl mutation	Patients who have failed two or more tyrosine kinase inhibitors
Dose (subcutaneous injection)	<ul style="list-style-type: none"> <li>Induction: 1.25 mg/m<sup>2</sup> two times a day for 14 days, every 28 days; up to 6 cycles</li> <li>Maintenance: as per induction phase, but 7 days treatment every 28 days</li> </ul>	<ul style="list-style-type: none"> <li>Induction: 1.25 mg/m<sup>2</sup> two times a day for 14 days, every 28 days; up to 6 cycles</li> <li>Maintenance: as per induction phase, but 7 days treatment every 28 days</li> </ul>
Primary endpoints	<ul style="list-style-type: none"> <li>Cytogenetic response</li> <li>Hematologic response (chronic, accelerated, blast phase)</li> </ul>	<ul style="list-style-type: none"> <li>Cytogenetic response</li> <li>Hematologic response (chronic, accelerated, blast phase)</li> </ul>
Status	NDA & MAA submitted	Completed


# Hematologic Responses in Patients Treated with Omapro




Median response duration (months)

9.1 (0.7 – 30.)	6.6 (0.9 – 14.8)	2 (0.5 – 4.7)
4.8 (1.15 – 19.38)	3.1 (0.72 – 10.53)	2.5 (0.66 – 10.95)

# Cytogenetic Responses in Patients Treated with Omapro



# Development Timeline



# U.S. Commercial Strategy

- Initial sales and marketing promotional efforts directed at U.S. Hematology Centers of Excellence
- Key customer targets include
  - Key opinion leaders in hematology/oncology
  - Regional thought leaders
  - Patient advocacy and social media outlets
  - Payors
- Targeted specialty pharmacy distribution approach
- GMP validated manufacturing
  - Commercial manufacturing partnership with attractive Cost of Goods Sold

# Corporate Overview

# Strong Board and Senior Management Team

## Management

Greg Collier, PhD\*

Adam Craig, MD, PhD, MBA

James Campbell, PhD, MBA

Tom DeZao, BA

Tom O'Neil, BA, MBA

Katie Cairati, MS

Chief Executive Officer and Managing Director

Senior Vice President and Chief Medical Officer

Chief Financial Officer and Chief Operating Officer

Senior Vice President and Chief Commercial Officer

Vice President of Finance and Administration

Senior Director of Regulatory Affairs

## Board of Directors

Brett Heading, LLB (Chairman)

Dan Janney, BA, MBA

Geoff Brooke, MBBS, MBA

Elmar Schnee, BCom Mkting

George Morstyn, MBBS, PhD

Jean-Luc Tétard

McCullough Robertson Lawyers

Alta Partners

GBS Venture Partners

CEO, Merck Serono

Former SVP and CMO, Amgen

President, Stragen Pharma

# Financial Snapshot

Financial Parameter	
Shares (ASX: CXS)	283 million
Market capitalization*	A\$ 280 million
Cash held	A\$ 17.6 million (as of 30 June 2009)
Hospira upfront	A\$ 17.8 million
Significant Shareholders	Alta Partners (15%), Stragen Pharma (13%), Orbis Investments (9%), Merck Serono (9%), GBS (8%)

\*Effective 4 January 2010  
USD/AUD approximately 0.90

# Key Events

Event	Timing
✓ Establish corporate partnership for EU	H2 2009
Omapro (omacetaxine) ODAC meeting	10 Feb 2010
Targeted approval of Omapro (omacetaxine) in USA	H1 2010
Targeted approval of omacetaxine in Europe	Q3 2010

# Summary

- Omapro is an active drug with a different mechanism of action than current TKIs
- Myelosuppression is the most common side effect and is normally manageable and reversible
- NDA under review with targeted approval in H1, 2010
- MAA under review with targeted approval in Q4, 2010
- U.S. commercial launch of Omapro targeted for H2, 2010
- Omacetaxine partnered in EU, the Middle East and parts of Africa with Hospira
- Strong leadership team and blue chip investors

# Contacts

## Australia

Level 4

199 Moorabool St,  
Geelong, Victoria 3220

Tel: +61 3 5223 9900

## USA

Suite 100

3715 Haven Avenue,  
Menlo Park, CA 94025

Tel: +1 650 474 9800

[www.chemgenex.com](http://www.chemgenex.com)